Literature DB >> 31816154

Impact of pre-existing hypertension and control status before atrial fibrillation onset on cardiovascular prognosis in patients with non-valvular atrial fibrillation: A real-world database analysis in Japan.

Kazuomi Kario1, Toru Abe1, Hiroshi Kanegae1,2.   

Abstract

Hypertension is an important risk factor for non-valvular atrial fibrillation (NVAF) and its prognosis. However, there is no study to clarify the impact of pre-existing hypertension and BP control status before the onset of AF on the prognosis after the onset of AF. This retrospective real-world cohort analysis used data from the Japan Medical Data Center Co., Ltd database. The presence of NVAF and hypertension, plus the occurrence of adverse events, was based on ICD-10 codes in the database. The primary composite AF-related cardiovascular event end point included ischemic stroke, hemorrhagic stroke, and acute myocardial infarction. Of the 21 523 patients identified as having new-onset NVAF between January 2005 and June 2016, 7885 had blood pressure (BP) data before the onset of NVAF available and were included in the analysis (4001 with pre-existing hypertension and 3884 without pre-existing hypertension). The rate of primary composite end point events was 10.3 and 4.4 per 1000 patient-years in patients with and without hypertension, respectively (P < .001). In addition, lower systolic BP (<120 mm Hg) before the onset of NVAF was associated with a lower incidence of cardiovascular events after the development of NVAF (P < .001). This highlights the importance of earlier and tighter 24-hour BP control before the onset of NVAF in patients with hypertension, not only for reducing the occurrence of new-onset of NVAF, but also for reducing both hemorrhagic and ischemic cardiovascular events after the onset of NVAF.
© 2019 Wiley Periodicals, Inc.

Entities:  

Keywords:  atrial fibrillation; cardiovascular events; morbidity; mortality; pre-existing hypertension; stroke

Mesh:

Substances:

Year:  2019        PMID: 31816154      PMCID: PMC8030061          DOI: 10.1111/jch.13755

Source DB:  PubMed          Journal:  J Clin Hypertens (Greenwich)        ISSN: 1524-6175            Impact factor:   3.738


  34 in total

1.  Rivaroxaban versus warfarin in nonvalvular atrial fibrillation.

Authors:  Manesh R Patel; Kenneth W Mahaffey; Jyotsna Garg; Guohua Pan; Daniel E Singer; Werner Hacke; Günter Breithardt; Jonathan L Halperin; Graeme J Hankey; Jonathan P Piccini; Richard C Becker; Christopher C Nessel; John F Paolini; Scott D Berkowitz; Keith A A Fox; Robert M Califf
Journal:  N Engl J Med       Date:  2011-08-10       Impact factor: 91.245

Review 2.  The Japanese Society of Hypertension Guidelines for the Management of Hypertension (JSH 2019).

Authors:  Satoshi Umemura; Hisatomi Arima; Shuji Arima; Kei Asayama; Yasuaki Dohi; Yoshitaka Hirooka; Takeshi Horio; Satoshi Hoshide; Shunya Ikeda; Toshihiko Ishimitsu; Masaaki Ito; Sadayoshi Ito; Yoshio Iwashima; Hisashi Kai; Kei Kamide; Yoshihiko Kanno; Naoki Kashihara; Yuhei Kawano; Toru Kikuchi; Kazuo Kitamura; Takanari Kitazono; Katsuhiko Kohara; Masataka Kudo; Hiroo Kumagai; Kiyoshi Matsumura; Hideo Matsuura; Katsuyuki Miura; Masashi Mukoyama; Satoko Nakamura; Takayoshi Ohkubo; Yusuke Ohya; Takafumi Okura; Hiromi Rakugi; Shigeyuki Saitoh; Hirotaka Shibata; Tatsuo Shimosawa; Hiromichi Suzuki; Shori Takahashi; Kouichi Tamura; Hirofumi Tomiyama; Takuya Tsuchihashi; Shinichiro Ueda; Yoshinari Uehara; Hidenori Urata; Nobuhito Hirawa
Journal:  Hypertens Res       Date:  2019-09       Impact factor: 3.872

3.  Apixaban versus warfarin in patients with atrial fibrillation.

Authors:  Christopher B Granger; John H Alexander; John J V McMurray; Renato D Lopes; Elaine M Hylek; Michael Hanna; Hussein R Al-Khalidi; Jack Ansell; Dan Atar; Alvaro Avezum; M Cecilia Bahit; Rafael Diaz; J Donald Easton; Justin A Ezekowitz; Greg Flaker; David Garcia; Margarida Geraldes; Bernard J Gersh; Sergey Golitsyn; Shinya Goto; Antonio G Hermosillo; Stefan H Hohnloser; John Horowitz; Puneet Mohan; Petr Jansky; Basil S Lewis; Jose Luis Lopez-Sendon; Prem Pais; Alexander Parkhomenko; Freek W A Verheugt; Jun Zhu; Lars Wallentin
Journal:  N Engl J Med       Date:  2011-08-27       Impact factor: 91.245

4.  Present status of anticoagulation treatment in Japanese patients with atrial fibrillation: a report from the J-RHYTHM Registry.

Authors:  Hirotsugu Atarashi; Hiroshi Inoue; Ken Okumura; Takeshi Yamashita; Naoko Kumagai; Hideki Origasa
Journal:  Circ J       Date:  2011-04-05       Impact factor: 2.993

5.  Prevalence of diagnosed atrial fibrillation in adults: national implications for rhythm management and stroke prevention: the AnTicoagulation and Risk Factors in Atrial Fibrillation (ATRIA) Study.

Authors:  A S Go; E M Hylek; K A Phillips; Y Chang; L E Henault; J V Selby; D E Singer
Journal:  JAMA       Date:  2001-05-09       Impact factor: 56.272

6.  Incidence of and risk factors for atrial fibrillation in older adults.

Authors:  B M Psaty; T A Manolio; L H Kuller; R A Kronmal; M Cushman; L P Fried; R White; C D Furberg; P M Rautaharju
Journal:  Circulation       Date:  1997-10-07       Impact factor: 29.690

7.  Increasing trends in hospitalization for atrial fibrillation in the United States, 1985 through 1999: implications for primary prevention.

Authors:  Wendy A Wattigney; George A Mensah; Janet B Croft
Journal:  Circulation       Date:  2003-07-28       Impact factor: 29.690

8.  Atrial fibrillation prevalence revisited.

Authors:  L Friberg; L Bergfeldt
Journal:  J Intern Med       Date:  2013-08-07       Impact factor: 8.989

Review 9.  Hypertension and Atrial Fibrillation: Doubts and Certainties From Basic and Clinical Studies.

Authors:  Paolo Verdecchia; Fabio Angeli; Gianpaolo Reboldi
Journal:  Circ Res       Date:  2018-01-19       Impact factor: 17.367

10.  Diagnostic accuracy of a new algorithm to detect atrial fibrillation in a home blood pressure monitor.

Authors:  Tomoyuki Kabutoya; Yasushi Imai; Satoshi Hoshide; Kazuomi Kario
Journal:  J Clin Hypertens (Greenwich)       Date:  2017-09-01       Impact factor: 3.738

View more
  7 in total

1.  QTc Interval is Associated with Atrial Fibrillation in Individuals with Metabolic Syndrome Phenotype.

Authors:  Ming-Chuan Lee; Yu-Tsang Wang; Yu-Ju Li; Ching-Yi Tsai; Su-Te Chen; Wun-Jyun Jhuang; Meng-Chi Chang; Mei-Yu Chien; Hsiang-Chun Lee
Journal:  Int J Gen Med       Date:  2022-07-15

2.  Impact of pre-existing hypertension and control status before atrial fibrillation onset on cardiovascular prognosis in patients with non-valvular atrial fibrillation: A real-world database analysis in Japan.

Authors:  Kazuomi Kario; Toru Abe; Hiroshi Kanegae
Journal:  J Clin Hypertens (Greenwich)       Date:  2019-12-09       Impact factor: 3.738

3.  Perspectives on an ambulatory blood pressure monitoring device with novel technology for pulse waveform analysis to detect arrhythmias.

Authors:  Tomonori Watanabe; Naoko Tomitani; Kazuomi Kario
Journal:  J Clin Hypertens (Greenwich)       Date:  2020-08-30       Impact factor: 3.738

4.  Piezo1 Participated in Decreased L-Type Calcium Current Induced by High Hydrostatic Pressure via. CaM/Src/Pitx2 Activation in Atrial Myocytes.

Authors:  Yuan Fang; Qian Li; Xin Li; Guan-Hao Luo; Su-Juan Kuang; Xue-Shan Luo; Qiao-Qiao Li; Hui Yang; Yang Liu; Chun-Yu Deng; Yu-Mei Xue; Shu-Lin Wu; Fang Rao
Journal:  Front Cardiovasc Med       Date:  2022-02-17

5.  High prevalence of masked uncontrolled morning hypertension in elderly non-valvular atrial fibrillation patients: Home blood pressure substudy of the ANAFIE Registry.

Authors:  Kazuomi Kario; Naoyuki Hasebe; Ken Okumura; Takeshi Yamashita; Masaharu Akao; Hirotsugu Atarashi; Takanori Ikeda; Yukihiro Koretsune; Wataru Shimizu; Hiroyuki Tsutsui; Kazunori Toyoda; Atsushi Hirayama; Masahiro Yasaka; Takenori Yamaguchi; Satoshi Teramukai; Tetsuya Kimura; Jumpei Kaburagi; Atsushi Takita; Hiroshi Inoue
Journal:  J Clin Hypertens (Greenwich)       Date:  2020-11-15       Impact factor: 3.738

6.  Assessment of a new algorithm to detect atrial fibrillation in home blood pressure monitoring device among healthy adults and patients with atrial fibrillation.

Authors:  Tomonori Watanabe; Naoko Tomitani; Nobuhiko Yasui; Tomoyuki Kabutoya; Satoshi Hoshide; Kazuomi Kario
Journal:  J Clin Hypertens (Greenwich)       Date:  2021-02-01       Impact factor: 3.738

Review 7.  The HOPE Asia Network activity for "zero" cardiovascular events in Asia: Overview 2020.

Authors:  Kazuomi Kario
Journal:  J Clin Hypertens (Greenwich)       Date:  2020-02-24       Impact factor: 3.738

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.